Brookline Capital Acquisition Estimates NTLA FY2026 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Brookline Capital Acquisition dropped their FY2026 earnings per share (EPS) estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 26th. Brookline Capital Acquisition analyst L. Cann now expects that the company will post earnings per share of ($3.11) for the year, down from their previous estimate of ($2.13). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Brookline Capital Acquisition also issued estimates for Intellia Therapeutics’ FY2027 earnings at $15.05 EPS and FY2030 earnings at $78.43 EPS.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The firm had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. During the same quarter in the previous year, the company posted ($1.27) earnings per share. The business’s quarterly revenue was up 78.4% compared to the same quarter last year.

A number of other brokerages have also recently weighed in on NTLA. HC Wainwright boosted their price target on Intellia Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Wolfe Research reissued a “peer perform” rating on shares of Intellia Therapeutics in a research note on Wednesday, November 12th. Truist Financial restated a “buy” rating and issued a $14.00 target price (down from $25.00) on shares of Intellia Therapeutics in a report on Monday, November 10th. Barclays decreased their target price on Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, November 7th. Finally, Wedbush lowered their price target on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $17.90.

Intellia Therapeutics Trading Down 3.5%

NTLA stock opened at $13.78 on Monday. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.25. The company has a fifty day simple moving average of $11.89 and a 200 day simple moving average of $13.05. The firm has a market cap of $1.63 billion, a PE ratio of -3.60 and a beta of 2.09.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. AQR Capital Management LLC lifted its position in shares of Intellia Therapeutics by 154.1% in the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock worth $646,000 after acquiring an additional 55,118 shares during the period. Woodline Partners LP acquired a new position in shares of Intellia Therapeutics in the first quarter valued at $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Intellia Therapeutics by 8.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after purchasing an additional 38,521 shares during the period. Atria Investments Inc acquired a new stake in Intellia Therapeutics during the second quarter worth $96,000. Finally, Intellectus Partners LLC boosted its stake in Intellia Therapeutics by 3.8% during the second quarter. Intellectus Partners LLC now owns 85,975 shares of the company’s stock worth $806,000 after buying an additional 3,150 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

Insider Activity at Intellia Therapeutics

In other news, EVP Birgit C. Schultes sold 8,508 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares in the company, valued at approximately $907,488.93. The trade was a 7.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John M. Leonard sold 34,146 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the transaction, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,051 shares of company stock worth $488,600 in the last ninety days. 3.10% of the stock is currently owned by insiders.

Key Stories Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations: Intellia reported a smaller-than-expected loss (‑$0.83 vs. consensus ‑$0.99) and revenue of $23.0M (well above estimates), which investors view as proof of commercial progress and operational execution. Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
• Positive Sentiment: Pipeline and regulatory progress: FDA lifted the clinical hold on MAGNITUDE‑2 (nex‑z) and management outlined 2026 launch plans for lonvo‑z (HAE) with mid‑2026 Phase 3 readout expectations and a potential BLA in H2 2026 — milestones that materially de‑risk commercial timelines if achieved. Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2
• Positive Sentiment: Strong cash runway: Intellia ended 2025 with roughly $605M in cash, cash equivalents and marketable securities — a balance that supports continued clinical development and commercial preparation into the near‑term. Intellia Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” and set a $26 price target, signaling notable upside from current levels and providing dealer/retail validation for the bull case. Benzinga
• Neutral Sentiment: Broker estimates: Brookline Capital published a slate of near‑term quarterly EPS forecasts (all negative) but raised long‑range FY2028/FY2029 EPS projections, reflecting high uncertainty today but improved long‑term expectations if pipeline succeeds. MarketBeat Q4 coverage / analyst notes
• Neutral Sentiment: Earnings call detail: Management emphasized commercial readiness for lonvo‑z and clinical plans for nex‑z; transcripts and call highlights are available for deeper review. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Profitability and consensus outlook remain weak: the company still posts large negative margins and the consensus full‑year EPS forecast is deeply negative, keeping NTLA a high‑volatility, binary biotech bet until clinical/commercial milestones are met. MarketBeat: Q4 results and metrics
• Negative Sentiment: Market reaction: despite the positive operational news, the shares are trading lower today — likely reflecting profit‑taking, macro/sector pressure on biotech, and investor caution about execution risk and near‑term losses.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.